LY2183240

LY2183240 - Names and Identifiers

Name	5-([1,1'-biphenyl]-4-ylmethyl)-N,N-dimethyl-1H-tetrazole-1-carboxamide
Synonyms	LY2183240 LY 2183240 LY-2183240 MN-25 N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide 5-(biphenyl-4-ylMethyl)-N,N-diMethyl-1H-tetrazole-1-carboxaMide 5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide 5-([1,1'-biphenyl]-4-ylmethyl)-N,N-dimethyl-1H-tetrazole-1-carboxamide 1H-Tetrazole-1-carboxamide, 5-([1,1′-biphenyl]-4-ylmethyl)-N,N-dimethyl- 5-[[(1,1'-BIPHENYL)-4-YL]METHYL]-N,N-DIMETHYL-1H-TETRAZOLE-1-CARBOXAMIDE
CAS	874902-19-9

LY2183240 - Physico-chemical Properties

Molecular Formula	C17H17N5O
Molar Mass	307.35
Density	1.21
Melting Point	87-88℃
Boling Point	506.1±53.0 °C(Predicted)
Solubility	Soluble in DMSO
Appearance	White to off-white solid.
Color	White
pKa	0.01±0.10(Predicted)
Storage Condition	Sealed in dry,2-8°C
Stability	Stable for 1 year as supplied. Solutions in DMSO of ethanol may be stored at -20°C for up to 1 month
Use	LY2183240 is a potent inhibitor of FAAH which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models. LY-2183240 has relatively poor selectivity and also inhibits several other enzyme side targets. Consequently, it was never developed for clinical use, though it remains widely used in research, and has also been sold as a designer drug.
Target	CUCQDDZYZNBQFE-KUNNFNOCSA-N

LY2183240 - Risk and Safety

Hazard Symbols	Xn - Harmful
Risk Codes	22 - Harmful if swallowed

LY2183240 - Reference

Reference

1: Köfalvi A, Lemos C, Martín-Moreno AM, Pinheiro BS, García-García L, Pozo MA, Valério-Fernandes Â, Beleza RO, Agostinho P, Rodrigues RJ, Pasquaré SJ, Cunha RA, de Ceballos ML. Stimulation of brain glucose uptake by cannabinoid CB(2) receptors and its therapeutic potential in Alzheimer's disease. Neuropharmacology. 2016 Mar 11. pii: S0028-3908(16)30087-9. doi: 10.1016/j.neuropharm.2016.03.015. [Epub ahead of print] PubMed PMID: 26976670.
2: Nicolussi S, Chicca A, Rau M, Rihs S, Soeberdt M, Abels C, Gertsch J. Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent. Biochem Pharmacol. 2014 Dec 15;92(4):669-89. doi: 10.1016/j.bcp.2014.09.020. Epub 2014 Nov 4. PubMed PMID: 25283614.
3: Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y. Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products. Forensic Sci Int. 2014 Oct;243:1-13. doi: 10.1016/j.forsciint.2014.03.013. Epub 2014 Mar 27. PubMed PMID: 24769262.
4: Gonzalez-Islas C, Garcia-Bereguiain MA, Wenner P. Tonic and transient endocannabinoid regulation of AMPAergic miniature postsynaptic currents and homeostatic plasticity in embryonic motor networks. J Neurosci. 2012 Sep 26;32(39):13597-607. PubMed PMID: 23015449; PubMed Central PMCID: PMC3470113.
5: Powers MS, Barrenha GD, Mlinac NS, Barker EL, Chester JA. Effects of the